Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution

– ARCALYST^® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth –
– ARCALYST 2024 expected net product revenue increased to $410 - $420 million –
– Life DisRPted ^™ disease awareness campaign for recurrent pericarditis launched in partnership with NHL Hall of Famer, Henrik Lundqvist, and GRAMMY^® Award-winning singer-songwriter, Carly Pearce –
– Kiniksa expects to remain cash flow positive on an annual basis –
– Conference call and webcast scheduled for 8:30 am ET today –

Read more at globenewswire.com